Skip to main content
. 2024 Apr 9;12(4):828. doi: 10.3390/biomedicines12040828

Figure 1.

Figure 1

Overview of the available treatments of kidney disease. APRIL, a proliferation inducing ligand; CKD, chronic kidney disease; ET1-AT1, endothelin 1—angiotensin II receptor type 1; GLP1, glucagon-like peptide 2; HIF, hypoxia-inducible factor; MRA, mineralocorticoid receptor antagonist; RNA, ribonucleic acid; SGLT2, sodium-glucose cotransporter 2.